Tygacil - Broad-Spectrum Antibiotic for Empiric Treatment of Serious Infections

Print

Mortality rates are twice as high among patients infected with pathogens resistant to antibiotic therapy compared with those that are susceptible.
 
«Back




Home
New On This Site
Products & Services
Company A-Z
Industry Projects
White Papers
Jobs & Careers
Press Releases
Events & Exhibitions
Newsletter
Advertise With Us
About Us
Client Area

For every phase of your drug development